ArticleBioinformation2025
CY-TB skin test: Detect and defeat.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current laboratory diagnostics for tuberculosis: from conventional approaches to next-generation molecular and immunological technologies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Latent Tuberculosis Infection (LTBI) is a sustained immune response to Mycobacterium tuberculosis without clinical evidence of active disease, representing a substantial reservoir, contributes to the global burden of tuberculosis (TB). To address these gaps, Cy-Tb test (formerly C-Tb), developed by the Serum Institute of India, Pune, has been introduced under NTEP policy, combines the operational simplicity of TST with the specificity of IGRAs, expanded the coverage of high-risk groups and household contacts of pulmonary TB patients. Cy-Tb represents a next-generation LTBI diagnostic solution that supports early detection, operational alignment with point-of-care testing, cost-effectiveness, integration potential into national programs and contributes significantly towards the goal of TB elimination in India by 2025 and globally by 2035.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.